Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7099MR)

This product GTTS-WQ7099MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7099MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15212MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ13396MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ8633MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ692MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ9184MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ5155MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ4680MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ1345MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-806
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW